NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Molecular Partners AG MOLN
7 fiscal years on record · CHF · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
CHF 0.00
Revenue, FY2025 · full 7-year series below
Revenue CHF M
Net income CHF M
FY2025 · Revenue 0.0 · Net income -61.7
100.0M200.0M-25.0M-50.0M
201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
·
Operating margin
Net margin
FY2024 · Operating -1231.7% · Net -1087.4%
-500%-1000%
201920222025
ROE
FY2025 · ROE -55.5%
20%40%60%-20%-40%-60%
201920222025
Three returns, three denominators.
Each CHF of equity lost 56 cents this year.
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · CHF
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue CHF B | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 |
| Operating income CHF B | −0.1 | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.0 |
| EBITDA CHF B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax CHF B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| Net income CHF B | −0.1 | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.0 |
| Free cash flow CHF B | −0.1 | −0.1 | −0.1 | 0.1 | −0.1 | −0.0 | −0.0 |
| EPS, diluted CHF | −1.65 | −1.59 | −1.89 | 3.54 | −2.06 | −2.51 | −1.69 |
| Dividend / sh CHF | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — |
| ROE % | −55.5 | −34.0 | −30.1 | 68.8 | −59.5 | −77.8 | −67.0 |
| Shares out B | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 26 reconciliationsAUDITED
Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code V8
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019